PT3801526T - Formas mono-hidratas e cristalinas de 6-[(3s,4s)-4-metil- 1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran- 4-il-7h-imidazo[1,5-a]pirazin-8-ona - Google Patents

Formas mono-hidratas e cristalinas de 6-[(3s,4s)-4-metil- 1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran- 4-il-7h-imidazo[1,5-a]pirazin-8-ona

Info

Publication number
PT3801526T
PT3801526T PT198079659T PT19807965T PT3801526T PT 3801526 T PT3801526 T PT 3801526T PT 198079659 T PT198079659 T PT 198079659T PT 19807965 T PT19807965 T PT 19807965T PT 3801526 T PT3801526 T PT 3801526T
Authority
PT
Portugal
Prior art keywords
pyrazin
tetrahydropyran
pyrrolidin
pyrimidin
ylmethyl
Prior art date
Application number
PT198079659T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of PT3801526T publication Critical patent/PT3801526T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PT198079659T 2018-05-25 2019-05-23 Formas mono-hidratas e cristalinas de 6-[(3s,4s)-4-metil- 1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran- 4-il-7h-imidazo[1,5-a]pirazin-8-ona PT3801526T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676381P 2018-05-25 2018-05-25
US201962788323P 2019-01-04 2019-01-04

Publications (1)

Publication Number Publication Date
PT3801526T true PT3801526T (pt) 2024-03-26

Family

ID=68617192

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198079659T PT3801526T (pt) 2018-05-25 2019-05-23 Formas mono-hidratas e cristalinas de 6-[(3s,4s)-4-metil- 1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran- 4-il-7h-imidazo[1,5-a]pirazin-8-ona

Country Status (22)

Country Link
US (2) US12006319B2 (https=)
EP (2) EP4349403A3 (https=)
JP (2) JP7818900B2 (https=)
KR (1) KR102923255B1 (https=)
CN (2) CN112469413B (https=)
AU (1) AU2019275075B2 (https=)
BR (2) BR122023022641A2 (https=)
CA (1) CA3100988A1 (https=)
DK (1) DK3801526T3 (https=)
ES (1) ES2975792T3 (https=)
FI (1) FI3801526T3 (https=)
HR (1) HRP20240363T1 (https=)
HU (1) HUE065709T2 (https=)
IL (1) IL278875A (https=)
LT (1) LT3801526T (https=)
MA (1) MA52792A (https=)
MX (2) MX2020012636A (https=)
PL (1) PL3801526T3 (https=)
PT (1) PT3801526T (https=)
SI (1) SI3801526T1 (https=)
WO (1) WO2019226944A1 (https=)
ZA (1) ZA202401459B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240082T1 (hr) 2015-07-07 2024-03-29 H. Lundbeck A/S Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
FI3801526T3 (fi) 2018-05-25 2024-03-20 Cardurion Pharmaceuticals Inc 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
CN114072151A (zh) * 2019-05-07 2022-02-18 伊马拉公司 用于治疗地中海贫血的pde9抑制剂
AU2021370658A1 (en) * 2020-10-27 2023-06-08 Cardurion Pharmaceuticals, Inc. Pde9 inhibitors for treating cardiac failure

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (https=) 1972-06-16 1978-05-11
JPS5318013B2 (https=) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
IL114852A (en) 1994-08-08 2000-02-29 Debiopharm Sa Pharmaceutically stable preparation of oxaliplatinum
DE69524639T2 (de) 1994-10-13 2002-08-08 Peptech Ltd., North Ryde Modifizierte mehrfach ungesättigte fettsäuren
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
KR100569319B1 (ko) 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
CZ20012627A3 (cs) 1999-01-20 2002-01-16 Arzneimittelwerk Dresden Gmbh Pouľití imidazo [1,5-a] pyrido [3,2-e]pyrazinonů jako léčiva
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
AU5319499A (en) 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US20040006248A1 (en) 2000-06-28 2004-01-08 Zambon Group S.P.A Process for the preparation of nitroalkenes
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
DE60220766T2 (de) 2001-03-02 2008-03-06 Debiopharm S.A. Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
IL158322A0 (en) 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
JPWO2002102364A1 (ja) 2001-06-18 2004-09-30 山田　幸子 ＰＰＡＲγ作動性医薬組成物
US6998395B2 (en) 2001-08-17 2006-02-14 University Of Pittsburg, Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
EP1444009A1 (en) 2001-11-02 2004-08-11 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
JP4652685B2 (ja) 2001-11-06 2011-03-16 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
EP2384750A1 (en) 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
WO2005041972A1 (en) 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
CA2554735A1 (en) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8241670B2 (en) 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US7776916B2 (en) 2004-04-28 2010-08-17 The Uab Research Foundation Nitrated lipids and methods of making and using thereof
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1772149A1 (en) 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
WO2006055965A2 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP1817009A2 (en) 2004-11-24 2007-08-15 Spi Pharma, Inc. Orally disintegrating compositions
AU2011202664B2 (en) 2004-12-08 2012-04-05 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2008008767A2 (en) 2006-07-14 2008-01-17 Cedars-Sinai Medical Center Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
JP2009545527A (ja) 2006-07-19 2009-12-24 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 粘膜炎の治療用の組成物及び方法
WO2008029589A1 (en) 2006-09-08 2008-03-13 Tokuyama Corporation Method and equipment for producing group-iii nitride
CA2671980C (en) 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
EP2120920A4 (en) 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
CA2699483A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
EP2271929B1 (en) 2008-04-18 2015-11-25 The University of Utah Research Foundation Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2320903B1 (en) 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
JP2012513774A (ja) 2008-12-31 2012-06-21 ニトロメガ コーポレーション ニトロ脂肪酸を含有する栄養補助物
US8937194B2 (en) 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
US20120136057A1 (en) 2009-07-29 2012-05-31 Phenomenome Discoveries Inc. Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
KR20120130078A (ko) 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
KR20130054249A (ko) 2010-03-15 2013-05-24 울리히 디에츠 공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도
US8563609B2 (en) 2010-05-13 2013-10-22 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
JP2013534930A (ja) 2010-06-28 2013-09-09 コンプレクサ，インコーポレイテッド 糖尿病を治療するための多成分調剤
RU2603140C2 (ru) 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2013051639A1 (ja) 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体
SG11201502728WA (en) 2011-10-10 2015-05-28 Lundbeck & Co As H Pde9i with imidazo pyrazinone backbone
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
JP6038184B2 (ja) 2012-02-01 2016-12-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ リボヌクレオチドレダクターゼ阻害剤および使用方法
US10435367B2 (en) 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
EP2809317A4 (en) 2012-02-03 2015-07-22 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
EP2994165A4 (en) 2013-05-10 2017-01-04 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
WO2014204872A2 (en) 2013-06-14 2014-12-24 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
CN105744983B (zh) 2013-08-12 2019-12-27 纳米医学系统公司 用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
WO2015185499A1 (en) 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
WO2016161285A1 (en) 2015-04-02 2016-10-06 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
HRP20240082T1 (hr) * 2015-07-07 2024-03-29 H. Lundbeck A/S Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
DK3416964T3 (da) 2016-02-19 2021-02-22 Phoenix Molecular Designs 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
TN2018000383A1 (en) 2016-07-06 2020-06-15 H Lundbeck As Pde9 inhibitors for treatment of peripheral diseases.
DK3630772T3 (da) 2017-05-26 2024-02-05 Cardurion Pharmaceuticals Inc Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere
FI3801526T3 (fi) 2018-05-25 2024-03-20 Cardurion Pharmaceuticals Inc 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
EP3946348A4 (en) 2019-04-05 2023-08-02 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
CN114072151A (zh) 2019-05-07 2022-02-18 伊马拉公司 用于治疗地中海贫血的pde9抑制剂

Also Published As

Publication number Publication date
LT3801526T (lt) 2024-04-10
JP7818900B2 (ja) 2026-02-24
JP2021526134A (ja) 2021-09-30
DK3801526T3 (da) 2024-03-25
EP4349403A2 (en) 2024-04-10
BR112020024019A2 (pt) 2021-02-23
KR102923255B1 (ko) 2026-02-04
KR20210014662A (ko) 2021-02-09
BR122023022641A2 (pt) 2024-02-20
US20240199627A1 (en) 2024-06-20
CN112469413A (zh) 2021-03-09
CA3100988A1 (en) 2019-11-28
WO2019226944A1 (en) 2019-11-28
US12466832B2 (en) 2025-11-11
FI3801526T3 (fi) 2024-03-20
AU2019275075A1 (en) 2021-01-14
MX2020012636A (es) 2021-01-29
CN117843645A (zh) 2024-04-09
EP4349403A3 (en) 2024-06-05
EP3801526A4 (en) 2022-04-06
CN112469413B (zh) 2024-01-12
IL278875A (en) 2021-01-31
US12006319B2 (en) 2024-06-11
HRP20240363T1 (hr) 2024-06-07
US20210107911A1 (en) 2021-04-15
EP3801526B1 (en) 2023-12-27
AU2019275075B2 (en) 2024-11-28
ES2975792T3 (es) 2024-07-15
HUE065709T2 (hu) 2024-06-28
ZA202401459B (en) 2025-07-30
SI3801526T1 (sl) 2024-05-31
MX2023009562A (es) 2023-08-22
PL3801526T3 (pl) 2024-08-05
EP3801526A1 (en) 2021-04-14
JP2024095561A (ja) 2024-07-10
MA52792A (fr) 2021-04-14

Similar Documents

Publication Publication Date Title
IL278875A (en) Monohydrate and crystalline forms of 6-[(S4,S3)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo [5,1-A ]pyrazine-8-one
IL283531A (en) Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG11202101148UA (en) PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
EP3268000A4 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
IL190677A0 (en) Use of prolines for improving growth and/or yield
PL3436019T3 (pl) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania
IL276160A (en) A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
WO2008157563A3 (en) Deuterium-enriched clopidogrel
IL315082A (en) Antiviral compounds and methods for its production and use
IL326214A (en) Modified bicyclic heterocyclic YAP-TEAD and/or TAZ-TEAD inhibitors
IL326322A (en) Antiviral compounds and methods for their production and use
EA202092762A1 (ru) МОНОГИДРАТНАЯ И КРИСТАЛЛИЧЕСКАЯ ФОРМЫ 6-[(3S,4S)-4-МЕТИЛ-1-(ПИРИМИДИН-2-ИЛМЕТИЛ)ПИРРОЛИДИН-3-ИЛ]-3-ТЕТРАГИДРОПИРАН-4-ИЛ-7H-ИМИДАЗО[1,5-a]ПИРАЗИН-8-ОНА
HK40121795A (en) Antiviral compounds and methods of making and using the same
HK40121419A (en) Antiviral compounds and methods of making and using the same
HK40114456A (en) Pi3k-alpha inhibitors and methods of making and using the same
CA3300785A1 (en) Substituted heterocyclic carboxamindes and use thereof
HK40055527A (en) Oxynitidine derivatives useful as inhibitors of topoisomerase ib (top1) and/or tyrosyl-dna phosphodiesterase 1 (tdp1)
CA3267406A1 (en) Novel bicyclic heterocyclyl compound and use thereof
HK40037687A (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
AU2017903306A0 (en) DERIVATIVES OF 4-(IMIDAZO[1,2-b]PYRIDAZIN-3-YL) PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES
HK1260882A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
HK1099210A (en) Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection